Novo Nordisk is paying up to $5.2 billion for a San Francisco biotech working on liver disease

Dow Jones

Oct 09

MW Novo Nordisk is paying up to $5.2 billion for a San Francisco biotech working on liver disease

By Steve Goldstein

Novo Nordisk has inked a deal to buy a U.S.-listed biotech.

Novo Nordisk, the Danish drug manufacturer behind the weight-loss and diabetes drug Ozempic and other medications, said it's paying up to $5.2 billion to buy Akero Therapeutics, a biotech company with a drug in a late-stage trial to treat a fatal liver disease.

Terms call for Novo to buy Akero for $4.7 billion, or $54 a share, as well as a contingent-value right worth $500 million, or $6 per share.

Akero shares (AKRO) jumped 19% to $55.27 per share. Novo Nordisk's U.S.-listed shares (NVO) (DK:NOVO.B) slipped 2%.

Akero has a a drug in Phase 3 development for a treatment for metabolic dysfunction-associated steatohepatitis, or MASH.

Novo Nordisk points out that more than 40% of MASH patients also have Type 2 diabetes, and over 80% of MASH patients are overweight or living with obesity.

The Danish company said Akero's drug, which like Ozempic is injected once a week, could be a cornerstone therapy or potentially used with Novo Nordisk's weight-loss drug Wegovy.

Akero said the deal was reached after a comprehensive review by its board.

-Steve Goldstein

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

October 09, 2025 06:59 ET (10:59 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2574115618"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2574115618\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2574115618?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-09 18:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2574115618","market":"hk","top_or_hot":-1,"title":"Novo Nordisk is paying up to $5.2 billion for a San Francisco biotech working on liver disease","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> is paying up to $5.2 billion for a San Francisco biotech working on liver disease\n</p>\n<p>\n  By Steve Goldstein \n</p>\n<p>\n     Novo Nordisk has inked a deal to buy a U.S.-listed biotech. \n</p>\n<p>\n     Novo Nordisk, the Danish drug manufacturer behind the weight-loss and diabetes drug Ozempic and other medications, said it's paying up to $5.2 billion to buy <a href=\"https://laohu8.com/S/AKRO\">Akero Therapeutics</a>, a biotech company with a drug in a late-stage trial to treat a fatal liver disease. \n</p>\n<p>\n     Terms call for Novo to buy Akero for $4.7 billion, or $54 a share, as well as a contingent-value right worth $500 million, or $6 per share. \n</p>\n<p>\n     Akero shares (AKRO) jumped 19% to $55.27 per share. Novo Nordisk's U.S.-listed shares (NVO) (DK:NOVO.B) slipped 2%. \n</p>\n<p>\n     Akero has a a drug in Phase 3 development for a treatment for metabolic dysfunction-associated steatohepatitis, or MASH. \n</p>\n<p>\n     Novo Nordisk points out that more than 40% of MASH patients also have Type 2 diabetes, and over 80% of MASH patients are overweight or living with obesity. \n</p>\n<p>\n     The Danish company said Akero's drug, which like Ozempic is injected once a week, could be a cornerstone therapy or potentially used with Novo Nordisk's weight-loss drug Wegovy. \n</p>\n<p>\n     Akero said the deal was reached after a comprehensive review by its board. \n</p>\n<p>\n     -Steve Goldstein \n</p>\n<p>\n     This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 09, 2025 06:59 ET (10:59 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk is paying up to $5.2 billion for a San Francisco biotech working on liver disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk is paying up to $5.2 billion for a San Francisco biotech working on liver disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-09 18:59</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> is paying up to $5.2 billion for a San Francisco biotech working on liver disease\n</p>\n<p>\n  By Steve Goldstein \n</p>\n<p>\n     Novo Nordisk has inked a deal to buy a U.S.-listed biotech. \n</p>\n<p>\n     Novo Nordisk, the Danish drug manufacturer behind the weight-loss and diabetes drug Ozempic and other medications, said it's paying up to $5.2 billion to buy <a href=\"https://laohu8.com/S/AKRO\">Akero Therapeutics</a>, a biotech company with a drug in a late-stage trial to treat a fatal liver disease. \n</p>\n<p>\n     Terms call for Novo to buy Akero for $4.7 billion, or $54 a share, as well as a contingent-value right worth $500 million, or $6 per share. \n</p>\n<p>\n     Akero shares (AKRO) jumped 19% to $55.27 per share. Novo Nordisk's U.S.-listed shares (NVO) (DK:NOVO.B) slipped 2%. \n</p>\n<p>\n     Akero has a a drug in Phase 3 development for a treatment for metabolic dysfunction-associated steatohepatitis, or MASH. \n</p>\n<p>\n     Novo Nordisk points out that more than 40% of MASH patients also have Type 2 diabetes, and over 80% of MASH patients are overweight or living with obesity. \n</p>\n<p>\n     The Danish company said Akero's drug, which like Ozempic is injected once a week, could be a cornerstone therapy or potentially used with Novo Nordisk's weight-loss drug Wegovy. \n</p>\n<p>\n     Akero said the deal was reached after a comprehensive review by its board. \n</p>\n<p>\n     -Steve Goldstein \n</p>\n<p>\n     This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 09, 2025 06:59 ET (10:59 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2574115618","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2574115618","pubTimestamp":1760007540,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Novo Nordisk has inked a deal to buy a U.S.-listed biotech.Novo Nordisk, the Danish drug manufacturer behind the weight-loss and diabetes drug Ozempic and other medications, said it's paying up to $5.2 billion to buy Akero Therapeutics, a biotech company with a drug in a late-stage trial to treat a fatal liver disease.Terms call for Novo to buy Akero for $4.7 billion, or $54 a share, as well as a contingent-value right worth $500 million, or $6 per share.Akero shares  jumped 19% to $55.27 per share. Novo Nordisk's U.S.-listed shares   slipped 2%.Akero has a a drug in Phase 3 development for a treatment for metabolic dysfunction-associated steatohepatitis, or MASH.Novo Nordisk points out that more than 40% of MASH patients also have Type 2 diabetes, and over 80% of MASH patients are overweight or living with obesity.The Danish company said Akero's drug, which like Ozempic is injected once a week, could be a cornerstone therapy or potentially used with Novo Nordisk's weight-loss drug Weg","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4007":"制药","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4588":"碎股","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4599":"减肥药","BK4585":"ETF&股票定投概念","AKRO":"Akero Therapeutics","BK4505":"高瓴资本持仓","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4139":"生物科技","BK4532":"文艺复兴科技持仓"},"translate_title":"诺和诺德斥资52亿美元收购旧金山一家致力于肝病的生物技术公司","themeId":"7634fea479edb90013bb48394ae3ce34","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKRO":1,"NVO":1.5},"content_text":"MW Novo Nordisk is paying up to $5.2 billion for a San Francisco biotech working on liver disease\n\n\n  By Steve Goldstein \n\n\n     Novo Nordisk has inked a deal to buy a U.S.-listed biotech. \n\n\n     Novo Nordisk, the Danish drug manufacturer behind the weight-loss and diabetes drug Ozempic and other medications, said it's paying up to $5.2 billion to buy Akero Therapeutics, a biotech company with a drug in a late-stage trial to treat a fatal liver disease. \n\n\n     Terms call for Novo to buy Akero for $4.7 billion, or $54 a share, as well as a contingent-value right worth $500 million, or $6 per share. \n\n\n     Akero shares (AKRO) jumped 19% to $55.27 per share. Novo Nordisk's U.S.-listed shares (NVO) (DK:NOVO.B) slipped 2%. \n\n\n     Akero has a a drug in Phase 3 development for a treatment for metabolic dysfunction-associated steatohepatitis, or MASH. \n\n\n     Novo Nordisk points out that more than 40% of MASH patients also have Type 2 diabetes, and over 80% of MASH patients are overweight or living with obesity. \n\n\n     The Danish company said Akero's drug, which like Ozempic is injected once a week, could be a cornerstone therapy or potentially used with Novo Nordisk's weight-loss drug Wegovy. \n\n\n     Akero said the deal was reached after a comprehensive review by its board. \n\n\n     -Steve Goldstein \n\n\n     This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 09, 2025 06:59 ET (10:59 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}